Cebranopadol Data Presented at World Institute of Pain

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cebranopadol Data Presented at World Institute of Pain Congress Highlight Clinically Significant Reductions in Pain, Low Abuse Deterrent Potential and a Favorable Respiratory Profile

NEWARK, Calif., May 23, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ: DEPO ) today announced that clinical data from Phase IIb trials of cebranopadol in chronic lower back pain (cLBP) and diabetic peripheral neuropathy (DPN) as well as from the human abuse potential and respiratory depression studies conducted by Grünenthal GmbH (“Grünenthal”) were presented this weekend at the 8th World Congress of the World Institute of Pain (WIP) in New York, New York. Cebranopadol is a novel, first-in-class analgesic in development for the treatment of moderate to severe chronic nociceptive and neuropathic pain. In December 2015, Depomed acquired the U.S. and Canadian rights to cebranopadol from Grünenthal.

Poster 160480 “Cebranopadol: A Novel First-In-Class Analgesic in Development for Chronic Pain Conditions – Results from a Human Abuse Potential Study in Non-Dependent Recreational Opioid Users” reported data from a Phase I study of 48 healthy, non-dependent recreational opioid users.  The study assessed the abuse potential of three different orally administered doses of cebranopadol (200, 400 and 800 μg), placebo and two doses of hydromorphone (8 and 16 mg) as a comparator to rate “drug liking”, a traditional endpoint for this type of study.  Data show that, as expected, hydromorphone generated a dose-dependent increase in likeability, whereas placebo showed little likeability with cebranopadol at therapeutic doses exhibiting similar likeability scores to placebo. Link to abstract: http://wip2016.kenes.com/scientific-program-(...z87hZ3n8qQ

Poster 160319 “Cebranopadol: A Novel, First-In-Class Analgesic:  Efficacy, Safety, Tolerability in Patients with Mixed Chronic Low Back Pain” reviewed data from the Phase IIb trial of 635 patients with moderate-to-severe cLBP.  This randomized, double-blind, placebo- and active-controlled, five-arm, monotherapy trial assessed the analgesic efficacy, safety, and tolerability of once daily oral dose of cebranopadol at three fixed doses (i.e., 200, 400, and 600 μg) compared to placebo and tapentadol prolonged release, as the active comparator. Data show all three doses of cebranopadol resulted in robust, clinically and statistically significant, and dose-dependent improvements in pain, with p values of 0.0095, 0.0122, and 0.0021 for 200, 400, and 600 μg, respectively, compared to placebo.   Link to abstract: http://wip2016.kenes.com/scientific-program-(...z8hbJ3n8qQ

Poster 160303 “Cebranopadol: A Novel, First-In-Class Analgesic in Development for Chronic Pain Conditions – Effects on Respiration in Healthy Human Volunteers” reported data from a Phase I trial of 12 healthy male subjects. This study assessed the effects of a single oral dose of cebranopadol (600 μg) compared to an intravenous dose of fentanyl (3.5 μg/kg). Data show that cebranopadol demonstrated a less pronounced and significantly delayed effect upon respiratory parameters (respiratory rate, ventilation and oxygen saturation) as compared to fentanyl, and that these changes appear to demonstrate a "ceiling effect". Link to abstract: http://wip2016.kenes.com/scientific-program-(...z7J1u7wCUk

Poster 160478 “Cebranopadol: A Novel, First-In-Class Analgesic: Efficacy, Safety, Tolerability in Patients with Pain Due to Diabetic Peripheral Neuropathy (DPN)” reviewed data from an exploratory Phase IIb trial of 314 patients with moderate to severe chronic pain due to DPN. This 5-arm, placebo- and active-controlled, parallel design trial compared the analgesic efficacy, safety and tolerability of once daily orally administered cebranopadol at 3 fixed doses (100, 300 and 600 μg) compared to placebo and pregabalin at 600 mg (300 mg twice-a-day) as the active comparator. Data show that at the highest dose of 600 μg, patients achieved clinically and statistically significant improvements in pain (p=0.0153).  The other two cebranopadol arms demonstrated a trend towards statistical significance, but did not achieve it in this exploratory trial.  Results also showed an absolute reduction in pain, which was -2.56, -2.28, and -2.24 on an 11-point scale for the 600, 300 and 100 μg doses, respectively as compared to -1.55 for placebo with evidence of a dose-response relationship.  Link to abstract:  http://wip2016.kenes.com/scientific-program-(...z8hbJ3n8qQ

Electronic copies of these posters are available upon request.

Top-line data from these trials were presented as part of Depomed’s Investor and Analyst Day in March. The replay of the presentation as well as the corresponding slide deck can be found in the Investors section of Depomed’s website at www.Depomed.com .

About Cebranopadol

Cebranopadol is a novel, first-in-class analgesic that acts as a nociceptin/orphanin FQ peptide (NOP) receptor and opioid receptor agonist. These mechanisms, which have been shown to synergize, result in both a comparable efficacy and broader analgesic spectrum versus standard mu-opioid receptor agonists as well as an improved safety profile, particularly as it pertains to respiratory depression. In total, cebranopadol has been studied in approximately 2,000 patients worldwide having completed several Phase II trials in painful diabetic peripheral neuropathy (PDPN), osteoarthritis (OA) and chronic lower back pain (cLBP) and is ready for Phase III development.

About Depomed

Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com .

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, risks related to the outcome of the Company’s ANDA litigation with Actavis, Alkem, Roxane and Watson, and the resulting exclusivity periods for NUCYNTA, NUCYNTA ER and NUCYNTA oral solution, as well as other risks detailed in the company's Securities and Exchange Commission filings, including the company's most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. There can be no assurance of a positive outcome in such litigation, or other assurance that actual results will be as expected or anticipated.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

INVESTOR CONTACT: Christopher Keenan VP, Investor Relations and Corporate Communications Depomed, Inc. 510-744-8000 ckeenan@depomed.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NetEase Margins Hold Firm as Game Revenue Slips Again

Updated Category News Views 123

A game publisher can look tired at the top line and still be doing plenty right underneath the hood. NetEase’s third-quarter 2026 report is that kind of animal: revenue eased, yet costs behaved, profit rebounded from the prior quarter, and the balance sheet remains absurdly well stocked. For investors in NASDAQ:NTES, this was not a clean victory lap. It was a reminder...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 112

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
Shanghai Import Expo Draws 4,000 Global Companies Again

Updated Category News Views 175

Shanghai spent last week making a rather pointed commercial argument: China wants to be seen buying, not merely selling. The ninth China International Import Expo, or CIIE, brought together more than 4,000 overseas companies and participants from 162 countries, regions and international organizations. That is a serious gathering by any reasonable measure, even if the...

Continue Reading
Würk's Bryte AI Targets Payroll's Costly Friction Points

Updated Category News Views 104

Payroll mistakes are the sort of paper cuts that suddenly turn into a hospital bill for an employer. Würk’s Nov. 19 launch of Bryte AI goes straight at that ugly reality in cannabis, beverage alcohol, and other heavily regulated workplaces, where a bad time entry, missed document, or misunderstood policy can create a far more expensive mess than ordinary office...

Continue Reading
Greenberg Traurig Builds Real Estate Bench Further

Updated Category News Views 47

Two real estate lawyers rarely move a market, but they can tell you where the legal work is getting sticky. Greenberg Traurig’s November 19 addition of Steven A. Fein and Kelsey Thayer is not some grand macroeconomic pronouncement, and nobody should pretend otherwise. It is, however, a pretty sensible read on the messy corners of commercial property finance: joint...

Continue Reading
CustomerInsights.AI Fast 500 Nod Tests Its AI Model

Updated Category News Views 44

Pharma’s analytics mess is exactly where CustomerInsights.AI has chosen to make its stand. The Scottsdale company’s inclusion in Deloitte’s 2026 Technology Fast 500, announced November 19, is a useful signal that its pitch is finding buyers: life-sciences businesses want AI to do actual commercial work, not sit in a lab demo collecting dust. Still, a Fast 500 badge...

Continue Reading
Securitize Tests the IPO Clock With Anthropic Tokens

Updated Category News Views 93

Anthropic did not even get a full trading day to itself before the tokenization crowd arrived. Securitize says Anthropic stock became available through Securitize Stocks on Solana on the company’s first day as a public company, a loud little signal that the old IPO playbook is being prodded from the edges. For investors, this is not merely another crypto-flavored...

Continue Reading
SDG&E's 21-Year Reliability Run Has Real Investor Weight

Updated Category News Views 37

Seventy minutes without power in a year is the sort of number most people ignore until their refrigerator quits humming. For San Diego Gas & Electric customers, though, it is a meaningful operating result: roughly 70 minutes annually from unplanned outages, on average, over the past decade, alongside fewer than one sustained outage per customer each year. SDG&E has also...

Continue Reading
Bella Rio's Proposed Preferred B Share Giveaway Plan

Updated Category News Views 46

A founder handing over two million of his own common shares is the sort of detail that makes investors stop stirring their coffee. Bella Rio Consulting, the company behind ROCK'N Vodka and Bella Rio Bourbon, says co-founder and Vice President Andy Roiniotis proposes to contribute 2,000,000 personally held Common shares for reclassification into Preferred Series B shares....

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 166

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading

Top 5 Most Recently Viewed Articles

Alvopetro Energy Ltd. Reports Record Sales Volumes

Updated Category News Views 127

Alvopetro Energy Ltd. Reports Strong Sales Volumes Alvopetro Energy Ltd. has reported commendable sales volumes for June 2025, reaffirming its position in the energy sector. The company, identified by its ticker symbols ALV (on the TSX Venture Exchange) and ALVOF (on the OTCQX), indicated a notable production rate of 2,514 barrels of oil equivalent per day (boepd) based...

Continue Reading
Mannatech Achieves New Stock Milestone with 52-Week High

Updated Category News Views 177

Mannatech Reaches Remarkable Peak in Stock Performance Mannatech, Incorporated (MTEX), a company dedicated to offering global wellness solutions, has recently achieved a noteworthy milestone by reaching a 52-week high with its stock price hitting $13.34. This impressive rise indicates a substantial increase in investor confidence, as the shares have surged by an...

Continue Reading
Exciting Developments Ahead for FAIRWOOD's Second Season

Updated Category News Views 240

FAIRWOOD Returns with a New Season The popular comedy series FAIRWOOD has officially been renewed for a second season, much to the delight of its fans. The show's creators, renowned musical duo Rusty and Clark Fairwood, along with the talented showrunner Bud Schaetzle, are back at the helm to deliver more engaging episodes. With all six episodes of the first season now...

Continue Reading
Celebrating Pioneers in the $6.8 Trillion Wellness Movement

Updated Category News Views 330

Leaders Transforming the Global Wellness Economy The Global Wellness Summit (GWS), renowned for gathering visionaries in the $6.8 trillion wellness economy, recently wrapped up its 19th annual conference held at an upscale venue. This prestigious gathering celebrated outstanding contributions through the Global Wellness Awards, recognizing individuals who have made...

Continue Reading
CRED iQ & TractIQ Push $50B of Data into AI Era

Updated Category News Views 5

AI-Driven Innovation in Self-Storage Market Mark my words, folks, the marriage of data and AI is reshaping industries faster than a stock split on Wall Street. CRED iQ and TractIQ are venturing into this fast-paced union. Just north of Philadelphia, CRED iQ has sealed a deal with TractIQ, a frontrunner in self-storage data solutions, to funnel a cool $50 billion worth of...

Continue Reading